When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Biological therapy for inflammatory bowel disease - Wikipedia

   en.wikipedia.org/wiki/Biological_therapy_for...

   The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel diseaseBiological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]

3. Infliximab - Wikipedia

   en.wikipedia.org/wiki/Infliximab

   Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. [48] It has a serum half-life of 9.5 days and can be detected in serum 8 weeks after infusion treatment. [48]

4. Biological response modifier - Wikipedia

   en.wikipedia.org/wiki/Biological_response_modifier

   [4] [9] Adverse effects may be class-dependent, and so switching to a biologic of another class may ameliorate those effects. [ 7 ] Potential serious adverse effects include allergic reactions , liver damage, cancer, and serious infections including tuberculosis , pneumonia , staph infection , and fungal infection .

5. US FDA proposes to remove switching study requirement for ...

   www.aol.com/news/us-fda-proposes-remove...

   The FDA has generally recommended switching studies to show evidence of interchangeability of a biosimilar. Regulatory reform is needed so patients can more easily access biosimilars and draw ...

6. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   Cetrelimab [5] mab: human: PD-1: cancer Cetuximab [32] Erbitux: mab: chimeric: Epidermal growth factor receptor (EGFR) Y: metastatic colorectal cancer and head and neck cancer: Cibisatamab [5] mab: humanized: CEACAM5: cancer Cilgavimab [29] mab: human: spike protein receptor binding domain (RBD) of SARS-CoV-2: US emergency use authorization ...

7. US FDA approves two biosimilars for blockbuster eye drug Eylea

   www.aol.com/news/us-fda-approves-two-biosimilars...

   The agency approved Biocon Biologics' Yesafili as well as Samsung Bioepis and Biogen's Opuviz, while also allowing interchangeability, or the drug's substitution with biosimilars without the need ...